Henan Lingrui Pharmaceutical Co (600285) Fair Value & Analysis
Healthcare · CN · Market cap 12.6B CNY
Fair value as of: Aug 8, 2026
From 24 valuation models · updated 2 days ago
Share price +1.6% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The model range is unusually wide (¥13.44 to ¥35.87). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 8, 2026.
How to read this chart
60‑month range ¥6.73 – ¥24.04 · fair‑value band ¥13.44 – ¥35.87 · the ¥22.24 price screens below the ¥23.12 fair value. Dashed = 300-day average. As of Aug 8, 2026.
Analysis
Henan Lingrui Pharmaceutical Co (600285) currently trades at ¥22.24, while our model-based Fair Value estimate is ¥23.12, implying the stock looks roughly 4.0% fairly valued today. The Quality Score stands at 72/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Henan Lingrui Pharmaceutical Co generated revenue of 4.0B CNY at a net margin of 19.9%. Revenue grew 10.3% year over year. It earns a return on equity of 22.6%. Net debt stands at 8.8M CNY. Fundamentals as of Aug 8, 2026
Our scenario range runs from ¥13.44 (bear case) to ¥35.87 (bull case); at ¥22.24, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 5% below its 52-week high and 15% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 4%, 600285 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (¥27.59) versus Asset-Based (¥4.02). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 8, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 70 · Market factors (momentum, volatility) 62
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Henan Lingrui Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of drugs in China. It operates through Pharmaceutical and Healthcare Division; and Others segments. The company offers its products in ten dosage forms, such as adhesive plasters, tablets, capsules, granules, and tinctures, etc.
Full company description
Henan Lingrui Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of drugs in China. It operates through Pharmaceutical and Healthcare Division; and Others segments. The company offers its products in ten dosage forms, such as adhesive plasters, tablets, capsules, granules, and tinctures, etc. for various indications, including orthopedic, cardiovascular, cerebrovascular, dermatology, pediatrics, respiratory, and anesthesiology. Its products include Tongluoqutong plasters, Peiyuantongnao capsules, Danlutongdu tablets, stomachache free tablets, and Shenqi Hypoglycemic capsules; and Tongluo pain relief creams, Huoxuexiaotong tinctures, bone strengthening musk pain relief creams, indomethacin patches, abdominal soothing plasters, children's paracetamol and phenylephrine granules, children's kechuanling granules, montmorillonite powders, medical cooling patches, three yellow pearl creams, mometasone furoate creams, mupirocin ointments, bluestone particles, ke ning capsules, xiao chaihu tablets, and ruishuan fentanyl transdermal patches. The company also engages in industrial and real estate investment; technology research and development; ecological agriculture; and high-tech activities. Henan Lingrui Pharmaceutical Co., Ltd. was founded in 1992 and is headquartered in Xinyang, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Henan Lingrui Pharmaceutical Co reported revenue of ¥3.9B in FY2025 versus ¥2.7B in FY2021, a compound +9.4%/yr. Reported net income was ¥760M in FY2025, compounding +20.4%/yr from FY2021.
Watch 600285: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 626 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 8, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Henan Lingrui Pharmaceutical Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Henan Lingrui Pharmaceutical Co (600285) overvalued or undervalued?
What is the fair value of 600285?
What is the quality score of 600285?
What is the revenue of Henan Lingrui Pharmaceutical Co (600285)?
What is the net profit margin of 600285?
Does Henan Lingrui Pharmaceutical Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Henan Lingrui Pharmaceutical Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.